Adverse effects of GLP-1 receptor agonists: difference between revisions
Diff·revision 26 → 27·22:48, 26 Jun 2025
Difference between revision 26 and revision 27 of Adverse effects of GLP-1 receptor agonists. 3 lines changed; the page grew by 477 bytes.
| Revision 26 — 21:07, 10 Jun 2025 AnaesthesiaAoife (talk) clarify that the rodent finding has not been observed in humans 5,314 bytes ±0 | Revision 27 — 22:48, 26 Jun 2025 BiliaryBea (talk) expand §Gastrointestinal effects 5,791 bytes +477 | ||
|---|---|---|---|
| 41 | A resting heart-rate increase of two to four beats per minute is reported across the class, attributed to direct sinoatrial action. No adverse outcome has been associated with it in the completed outcome trials.{{r|drucker2018}} | 41 | A resting heart-rate increase of two to four beats per minute is reported across the class, attributed to direct sinoatrial action. No adverse outcome has been associated with it in the completed outcome trials.{{r|drucker2018}} |
| 42 | 42 | ||
| + | 43 | Injection-site reactions are generally mild and transient except with the microsphere formulation of [[Exenatide|exenatide]], where persistent nodules are attributable to the polymer matrix. Delayed gastric emptying has prompted revised preoperative guidance; see [[Aspiration risk under anaesthesia]]. Nothing here is medical advice.{{r|ada2024}} | |
| + | 44 | ||
| 43 | == References == | 45 | == References == |
| 44 | {{reflist}} | 46 | {{reflist}} |
| ⋮ | ⋮ | ||
| 46 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> | 48 | <ref name="wilding2021">Wilding JPH, Batterham RL, Calanna S, et al. "Once-weekly semaglutide in adults with overweight or obesity." ''New England Journal of Medicine'' 384(11):989–1002 (2021). PMID 33567185.</ref> |
| 47 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> | 49 | <ref name="nauck2016">Nauck MA, Meier JJ. "The incretin effect in healthy individuals and those with type 2 diabetes." ''The Lancet Diabetes & Endocrinology'' 4(6):525–536 (2016). PMID 26876794.</ref> |
| + | 50 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | |
| 48 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> | 51 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). PMID 37952131.</ref> |
| 49 | 52 |